Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001–2002  by Guzman, Maria G. et al.
International Journal of Infectious Diseases 16 (2012) e198–e203Epidemiological studies on dengue virus type 3 in Playa municipality, Havana,
Cuba, 2001–2002
Maria G. Guzman a,*, Angel Alvarez a, Susana Vazquez a, Mayling Alvarez a, Delﬁna Rosario a,
Otto Pelaez b, Guillermo Cruz c, Rosmari Rodriguez a, Alequis Pavon a, Annia Gonzalez c,
Luis Morier a, Dydie Ruiz a, Gustavo Kouri a, Scott B. Halstead d
aDepartment of Virology, PAHO/WHO Collaborating Center for the Study of Dengue and its Vector, ‘‘Pedro Kouri’’ Tropical Medicine Institute,
Autopista Novia del Mediodı´a km 6, PO Box 601, Marianao 13, Havana, Cuba
b Provincial Public Health and Epidemiology Center, Havana City, Cuba
cMunicipal Public Health and Epidemiology Center, Miramar, Playa, Havana, Cuba
d Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA
A R T I C L E I N F O
Article history:
Received 2 August 2010
Received in revised form 30 August 2011
Accepted 1 September 2011
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Dengue
Dengue hemorrhagic fever
Cuba
Pathogenesis
Epidemiology
Dengue virus type 3
S U M M A R Y
Objectives: Recognizing the uniqueness of secondary dengue virus (DENV)-1/3 dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) cases at an interval of 24 years, we sought to estimate DENV
infections as well as the ratios between mild disease and DHF/DSS by DENV infection sequence in Playa
District (Havana, Cuba) during the 2001–2002 outbreak of dengue virus type 3 (DENV-3).
Methods: A retrospective seroepidemiological study was conducted in 2003 in Playa District. Blood
samples were collected from a 1% random sample of residents and were studied for the prevalence of
dengue neutralizing antibodies.
Results: DENV-3 was found to have infected 7.2% (95% conﬁdence interval (95% CI) 6.0–8.4%) of
susceptible individuals (the entire cohort), the majority of whom experienced silent infections. Virtually
every individual who had a secondary infection in the sequence DENV-1 then DENV-3 became ill, with a
ratio of severe to mild cases of 1:35 (95% CI 1:67–1:23). Secondary infections in the sequence DENV-2/3
were less pathogenic than DENV-1/3. Mild disease accompanying secondary DENV2/3 occurred at a ratio
of 1:4.49 infections (95% CI 1:5.77–1:3.42) secondary infections.
Conclusions: The results obtained highlight the role of the infecting serotype and also the sequence of the
viral infection in the clinical outcome of a dengue infection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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During the past 50 years, dengue fever (DF) and dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS) have
emerged to become the major global arthropod-borne viral
infectious disease. DHF, identiﬁed in Southeast Asia during the
1950s, was ﬁrst noted in the Americas in 1981 and is now
widespread throughout the hemisphere.1,2 Studies in Thailand
identiﬁed sequential infections by different dengue viruses as a
fundamental risk factor for DHF/DSS.3,4 A mechanism of patho-
genesis postulated for this severe syndrome is antibody-depen-
dent enhancement (ADE), in which complexes of dengue virus and
non-neutralizing dengue antibodies infect mononuclear phago-
cytes with enhanced efﬁciency and increase the viral output per
infected cell.5,6 Many other factors, such as the infecting dengue* Corresponding author. Tel.: +53 7 2020450; fax: +53 7 2046051.
E-mail address: lupe@ipk.sld.cu (M.G. Guzman).
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doi:10.1016/j.ijid.2011.09.026virus (DENV) strain, the interval and sequence of infections, and
the genetic background and chronic disease status of the
individual, inﬂuence the ﬁnal outcome of a DENV infection.7,8
Cuba is surrounded by dengue-endemic countries. DENV type 1
(DENV-1) was introduced to Cuba in 1977 and infected 44.5% of the
population, resulting in more than 500 000 cases of non-
hospitalized disease.7,9,10 Four years later, in 1981, a DENV type
2 (DENV-2) Asian genotype was introduced, resulting in more than
400 000 cases, with 10 312 severe illnesses including 158 fatalities
(101 children).7,11 In 1997, following a long period of strong
nationwide Aedes aegypti control, an American Asian DENV-2 was
introduced in Santiago de Cuba, resulting in approximately 5000
cases, including 205 DHF/DSS cases with 12 deaths. Each of these
epidemics was the subject of retrospective population-based
seroepidemiological studies.12,13 Important observations from the
two epidemics involving infections in the sequence DENV-1/2
included the relative resistance of blacks to severe clinical
expression during secondary dengue infections compared to
whites,12 the high risk of young children to vascular permeabilityses. Published by Elsevier Ltd. All rights reserved.
M.G. Guzman et al. / International Journal of Infectious Diseases 16 (2012) e198–e203 e199accompanying a secondary DENV-2 infection,14 a month-to-month
increase in case fatality rates,15 the increased severity of secondary
DENV-1/2 infections (a DENV-2 infection in a previous immune
DENV-1 individual) occurring at an interval of 20 years compared
with 4 years,16 and a correlation of this enhanced severity with a
decrease in heterotypic DENV-1 neutralizing antibody titers with
the passage of time.17 These observations depended critically on
our being able to relate serologically deﬁned clinical dengue cases
to total dengue infections, primary and secondary, in the affected
populations. Epidemiological studies were made possible by the
comprehensive Cuban dengue surveillance system, by universal
access to health care for all patients, and to the sensitive and
speciﬁc dengue neutralizing antibody method adopted for
measuring dengue infections in open populations. As has been
demonstrated repeatedly, neutralizing antibodies are sufﬁciently
durable and speciﬁc to measure and identify primary and
secondary dengue infections accurately.12,18,19
In 2000, a 3-month limited outbreak of DENV type 4 (DENV-4)
was reported in Havana, resulting in 138 conﬁrmed cases.2 In June
2001, the nationwide dengue case surveillance system identiﬁed a
DENV type 3 (DENV-3) genotype III outbreak in Havana that
eventually expanded to involve 12 889 serologically conﬁrmed
cases, including 78 DHF/DSS and three fatalities (all in adults). All
severe dengue cases were hospitalized at the Institute of Tropical
Medicine, providing a unique opportunity for some of us to study
the clinical features of primary DENV-3 and secondary DENV-1/3
and DENV-2 /3 disease.20,21 No new conﬁrmed DENV-3 cases were
reported after April 2002.22–24 Recognizing the uniqueness of
secondary DENV-1/3 DHF/DSS cases in the literature and because
no secondary DENV-3 infections have ever been studied at an
interval of 24 years after DENV-1 and/or 20 years after DENV-2
infections, we thought it important to measure dengue infection in
a population cohort using a retrospective seroepidemiological
format. Accordingly, blood samples were collected from a 1%
random sample of the population of Playa District of Havana City in
late 2003. We report here estimates of DENV infections in Playa
during the 2001–2002 outbreaks. Previous serological data from
mild and DHF cases from the 2001–2002 outbreak allowed us to
estimate the ratios between mild disease and DHF/DSS in different
age groups by DENV infection sequence.20,21
2. Materials and methods
2.1. Study site
Havana, the capital city of Cuba, has 15 municipalities
(districts), 2 193 848 inhabitants, and a population density of
3040/km2. It is located in the northwest of the country, with a
geographical expanse of 720.84 km2 and an annual average
temperature of 25 8C. Playa District, located in the northern sector
of the city, has 182 964 inhabitants and a population density of
5057/km2. At the time of the epidemic the district was served by
253 family doctors (one family doctor per approximately 720
inhabitants) located in nine health areas and comprising the
primary health care system.22–24 By order of the Ministry of Health,
all patients with a provisional diagnosis of dengue who were
thought sufﬁciently ill to require hospitalization were admitted to
the hospital located within the Tropical Medicine Institute, ‘‘Pedro
Kouri’’ (IPK). The Virology Laboratory at IPK performed serological
tests on all reported suspected dengue patients during the 2001–
2002 epidemic.
2.2. The 2001–2002 epidemic of DENV-3
At the end of June 2001, a conﬁrmed dengue case was reported
in Playa District. In spite of all vector control efforts, by week 29, at4 weeks after transmission was detected, a second district reported
conﬁrmed dengue cases; by week 42, 14 of the 15 districts had
reported dengue transmission. Once dengue virus transmission
was detected, active case detection surveillance was established.
As part of the active surveillance, healthcare workers actively
visited every family daily looking for acute febrile cases and
suspected dengue cases. Patients were followed up for 6–7 days
both for clinical evolution as well as for serological study.24 Acute
and/or convalescent serum specimens from suspect cases were
submitted to a laboratory network for testing, in accordance with a
long-established system.24 A total of 72 162 serum samples,
collected 5–6 days after the onset of fever from febrile and
suspected dengue cases seen in the primary health care system or
emergency rooms of hospitals and polyclinics in the capital city,
were serologically studied for dengue IgM detection. IgM studies
were conducted ﬁrst at the laboratory of the Centro Provincial de
Higiene y Epidemiologia de Ciudad Habana (CPHE-CH) by
ultramicro-ELISA for dengue IgM detection.24 Positive samples
were conﬁrmed at the national reference center, the Tropical
Medicine Institute (IPK), by an IgM antibody capture ELISA (MAC-
ELISA).25–27 Viral isolation and PCR studies identiﬁed DENV-3
genotype III as the etiological agent of the epidemic.28 Dengue
syndromes were classiﬁed according to the guidelines for control
and prevention of dengue and DHF in the Americas.25 We believe
that almost all clinically overt dengue cases were reported during
this outbreak. This conclusion derives from the known strength of
the active dengue surveillance system and the requirement that
health facilities submit serum from all clinical cases for serological
and virological study. A total of 12 889 serologically conﬁrmed
cases (suspected dengue cases with a positive dengue IgM as
determined by MAC-ELISA) were identiﬁed; 7063 presented with
undifferentiated fever, 5748 with DF, and 78 with DHF, including
three fatalities.22–24 Among conﬁrmed cases, 1660 (12.9%) were
children younger than 15 years of age and 11 229 were adults
(87.1%); 52.4% were female and 47.6% were male. Dengue
transmission in Playa occurred over a period of 26 weeks, with
1826 conﬁrmed cases reported, including 20 DHF/DSS (Table 1). A
strong campaign of sanitation and vector control was initiated in
January 2002, and the epidemic was under control by the end of
March 2002, well before the expected end of the 2002 transmission
season of September.23,24 In this article, DF and undifferentiated
fever cases have been combined and are referred to as ‘mild’
disease.
2.3. Population-based seroepidemiological study
In November 2003, a representative sample of families in Playa
District was selected using family doctor household registries. For
the analysis it was assumed that all individuals were independent.
Using an equal probabilistic random sampling method, a sample
size was calculated, assuming a DENV-3 antibody prevalence of
15%, with a statistical power of 99% (b = 1) and 95% (a = 0.05) of
conﬁdence; 440 families were chosen from 253 family doctor
ofﬁces in Playa. A demographic and health questionnaire was
completed for each member of the selected families. From the 440
families, blood samples were collected from 1758 individuals of
whom 58.8% (n = 1034) were female, 41.2% (n = 724) were male,
64.2% (n = 1128) were white, 21.1% (n = 371) were mixed race, and
14.7% (n = 259) were black. In the 2000 census report for Playa
District the population was 43.3% male, 62.1% white, 24.3% mixed
race, and 13.6% black. Distributions between sample and census
data did not differ.
Using an institutional review board (IRB) sanctioned protocol
approved by the Institute of Tropical Medicine Human Use
Committee and following the precepts established by the
Declaration of Helsinki, trained survey teams made one or two
Table 1
Mild dengue and DHF/DSS cases by age group in the Playa District DENV-3
epidemic, 2001–2002
Age group (years) Dengue cases, Playa municipalitya Playa population
Undifferentiated and
dengue fevers
DHF/DSS
2–9 95 0 42 298
10–19 277 0
20–25 237 0 13 865
26–29 134 3 93 792
30–39 429 10
40–49 245 4
50–59 223 2
60–69 127 1 33 009
70–79 29 0
80 10 0
Total 1806 20b 182 964
DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; DENV-3, dengue
virus type 3.
a Serologically conﬁrmed cases.
b Nineteen DHF/DSS cases experienced a DENV-1/DENV-3 infection and one a
tertiary DENV-1/DENV-2/DENV-3 infection.21
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each household participant; parental consent was obtained for
children. A questionnaire was completed for every family member
recording general demographic data and history of dengue-like
illnesses during the 2001–2002 epidemic. Blood was collected by
ﬁnger-prick on two Nobuto type A ﬁlter papers (Toyo Roshi
International, Inc., Tokyo, Japan), in accordance with the manu-
facturer’s instructions.
2.4. Serological tests
Following the manufacturer’s instructions, blood on the ﬁlter
paper was eluted at 1:10 dilution in phosphate-buffered saline
(PBS) after overnight incubation at 4 8C. Filter paper eluates were
screened by ELISA inhibition method (EIM)20,26 to determine the
presence of anti-dengue IgG antibodies. Brieﬂy, polystyrene plates
(Costar) were adsorbed with human anti-dengue IgG at 10 mg/ml
concentration, in coating buffer, and incubated overnight at 4 8C.
The plates were blocked and 100 ml of DENV-3 antigen diluted 1/
40 in PBS plus 0.05% Tween 20 was added. After incubation, 100 ml
of eluates at 1:20 dilution was added. After washing, 100 ml of
human IgG anti-dengue conjugate diluted in PBS plus 0.05% Tween
20 and 2% fetal bovine serum (FBS) was added. Substrate was
added and the test was read at 492 nm. The inhibition percentage
was calculated using the following equation: inhibition % = [1 
(OD sample/OD negative control)]  100. Samples with 50%
inhibition were considered positive for anti-dengue IgG. All EIM-
positive samples were tested by plaque-reduction neutralization
test (PRNT).26,29–31 Neutralizing antibody to the four dengue
serotypes was measured using the single dilution (1:30) method
employed previously to identify dengue neutralizing antibodies
after the 1981 and 1997 epidemics.12,13,31,32 All eluates were
assayed for neutralizing antibodies on BHK-21 clone 15 cells in
triplicate wells, and mean plaque counts were calculated.
Brieﬂy, BHK-21 clone 15 cells were grown at 37 8C in complete
medium E-MEM (minimum essential medium with Earle’s
balanced salts) supplemented with 10% heat-inactivated FBS, 1%
penicillin/streptomycin, 10% L-glutamine, and sodium bicarbonate
to adjust the medium to pH 7.4–7.8. For antibody titration, 100 ml
of serum dilution was incubated for 1 h at 37 8C with 100 ml of the
virus working dilution, calculated to give 10–20 plaque-forming
units (pfu)/50 ml of the ﬁnal volume of virus–serum mixture. After
incubation, 50 ml of virus–serum mixture was added to the cell
suspension in triplicate. After 4 h incubation at 37 8C in a CO2atmosphere, each well received 0.5 ml of 3% medium viscosity
carboxymethyl cellulose made up in Earle’s minimum essential
medium without phenol red (MEM) with 10% heat-inactivated FBS,
1% glutamine 2 mM, and 100 U of penicillin plus 100 mg/ml
streptomycin. Infected cells were incubated for 5–9 days in the
same conditions as above depending on the serotype. After
incubation, plates were rinsed under tap water and stained with a
solution of naphthol blue black and acetic acid. Calculations of 50%
endpoint plaque reduction neutralization titers were made using
log probit paper.32 According to criteria previously used to study
known introductions of DENV-1 followed by DENV-2, serum that
reduced DENV plaques by 50% at a 1/30 serum dilution for a
single DENV was considered a prior primary infection; serum that
neutralized 50% plaques of two DENV were considered cases
immune to two viruses.12,13,20,21,33 Finally, neutralization by three
or four viruses was scored as prior infection by more than two
dengue infections.
The following strains were employed in the neutralization
tests: DENV-1, Angola (1988), DENV-2 A15/81, Cuba (1981),
DENV-3 116/00, Cuba (2000), and DENV-4, Dominica (1981).
DENV-1 and DENV-4 strains were obtained from the late Dr Robert
Shope, University of Texas Medical Branch.
To eliminate uncertainty about the extent of DENV-1 infections
among 20–25-year-olds who were young infants during the 1977–
1979 epidemic and possibly shielded from exposure to mosqui-
toes, this age group was omitted from the analysis of infections in
the sequence DENV-1 then DENV-3. Secondary dengue infection
rates were estimated using the age group 26–59 years.
2.5. Statistical analysis
Tests of statistical signiﬁcance for nominal and ordinal
qualitative variables used to compare the hypothesis of indepen-
dence between variables with the homogeneity test. A simple
binomial conﬁdence interval, as has been calculated in various
cases, assumes that all sampled individuals are independent.
Percentages of the prevalence of infections among the sampled
individuals were calculated with their 95% conﬁdence intervals
(95% CI). Data determined by Alvarez et al. were used for the
calculation of the ratios of infection of DF and DHF cases.20,21
3. Results
In December 2003, of 1758 individuals sampled, 41.4% (95% CI
39.1–43.7%) had neutralizing antibodies to one or more of the four
DENV serotypes (Table 2). Given extensive data documenting the
universal and lifetime longevity of DENV neutralizing antibodies
following infection,17,34,35 these antibodies are taken to reﬂect the
cumulative infection experience among the residents of Playa
District from known dengue virus introductions in the 1940s and
in 1977–1979, 1981, 2000, and 2001–2002.
DENV-3 antibodies were detected in 126 (7.2%, 95% CI 6.0–8.4%)
individuals in the entire cohort. According to history of dengue-like
illness recorded during the sample collection interview, 13.5% (95%
CI 11.9–15.1%) of the total individuals with DENV-3 antibody
developed a symptomatic infection. Considering these ﬁgures, and
applying a multiplication factor derived from the total and sample
population (182 964/1758 = 104), an estimated 13 104 (7.16%, 95%
CI 7.0–7.2%) individuals were infected in the whole district, with
approximately 1769 clinical cases (13.5%, 95% CI 12.9–14.0%). This
ﬁgure is very close to the total clinical cases (n = 1806) reported in
Playa municipality during the epidemic (Table 1).
From antibody prevalence in the cohort, we calculated primary
DENV-3, secondary DENV-1/3 and DENV-2/3, tertiary DENV-1+2/3
and DENV-2+4/3, and the quaternary infection rate occurring
during 2001–2002 in Playa District. A primary DENV-3 infection
Table 2
Prevalence of different combinations of dengue neutralizing antibodies in the sampled population resident in Playa District, Havana; December 2003
Age group, years Dengue viruses Negative Studied
sample
Monotypic Combined
1 2 3 4 1+2 1+3 1+4 2+3 2+4 3+4 1+2+3 1+2+4 1+3+4 2+3+4 1+2+3+4
n n n n n n n n n n n n n n n
2–19 0 0 17 0 0 0 0 0 0 0 0 0 0 0 0 292 309
20–25 10 2 2 1 3 0 0 4 1 0 1 0 0 0 0 113 137
26–39 62 25 5 4 39 1 0 5 6 0 11 4 0 1 1 489 892
40–59 89 32 7 5 67 5 1 3 10 0 13 2 0 0 5
60 41 117 4 2 52 0 1 10 16 0 17 9 0 4 10 137 420
Total 202 176 35 12 161 6 2 22 33 0 42 15 0 5 16 1031 1758
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monotypic DENV-3 antibodies observed in the sera from 309
individuals aged 2–19 years, who were born after the outbreak of
DENV-2 in 1981 (17/309 = 5.5%, 95% CI 4.4–6.6%). Applying this
infection rate to the total Playa population aged 2–19 years, of
42 298, there were 2326 primary DENV-3 infections in Playa,
among which were 372 mild cases (Table 1). As evidence of the
focal and limited nature of the DENV-4 introduction of 2000, only
scattered monotypic DENV-4 antibodies were observed in
individuals in the 26–59 years age group and none were observed
in individuals under the age of 19 years.
Although data are shown, dengue infection rates were not
estimated for individuals aged 60 years because in this age group
we could not differentiate DENV-2 antibodies from infections that
may have been acquired before or during the World War II period
from those infections that might have occurred in 1981.
Using DENV neutralizing antibody prevalence in the age group
26–59 years (Table 2), we calculated primary, secondary, and
tertiary DENV-3 infection rates. Secondary DENV-1/3 infection
rates were calculated from the number of individuals with DENV-1
+ DENV-3 antibodies in the survey. This number was divided by
estimated pre-outbreak monotypic DENV-1 immunes, comprising
monotypic DENV-1 immunes observed in 2003 and DENV-
1 + DENV-3 immunes (151 + 6), or 6/157 = 3.8% (95% CI 2.9–
4.7%). A similar strategy was used to estimate the secondary DENV-
2/3 infection rate, 8/65 = 12.3% (95% CI 10.8–13.8%), and tertiary
and quaternary infection rates. The combined DENV-3 infectionTable 3
Observed primary and estimated secondary, tertiary, and quaternary DENV-3 infections i
Playa District (population 93 792) during the 2001–2002 DENV-3 epidemic, Havana, C
Primary infections Secondary inf
DENV-3 DENV-1/3 
Infections in cohort 12 6 
Estimated DENV-3 infections, all Playa 1261.2 630.6 
Reported mild/DHF casesa 32/0 625/18 
Mild/estimated DENV-3 infections 1:39.4 1:1 
DHF/estimated DENV-3 infections 0 1:35 
DENV, dengue virus; DHF, dengue hemorrhagic fever.
a DF and DHF estimated ratios using data collected by Alvarez et al., 2006;20 Alvare
Table 4
Dengue antibody distribution by ethnic group and gender, Playa cohort, 2003
Ethnic groupa
White, n (%) Mixed, n (%) 
Any dengue 467 (41.40) 143 (38.54) 
Negative 661 (58.60) 228 (61.46) 
Total 1128 371 
a p = 0.52.
b p = 0.69.rate in heterotypic immunes was 45/381 = 11.8% (95% CI 10.3–
13.3%).
Applying an expansion factor derived from dividing the district
total by the serologically sampled Playa population aged 26–59
years (93 792/892 = 105.1), primary, secondary, tertiary, and
quaternary dengue infections were estimated for Playa District
during the 2001–2002 DENV-3 outbreak (Table 3).
As the ratios of overt disease in residents of Playa District
attributed to different DENV infection events had previously been
measured by Alvarez et al.,20 we extended these data to the 1031
individuals in this age group with mild illness (Table 1). This
analysis provides estimates of 32 primary DENV-3 infections, 625
secondary DENV-1/3 infections, 187 secondary DENV-2/3 infec-
tions, and 187 tertiary DENV infections. From this partition of
infection sequence among overt cases we used our estimates of
DENV-3 infection rates to calculate attack rates for mild and DHF/
DSS cases by infection sequence and parity in Playa District (Table
3). The ratio of mild disease to total primary infections with the
DENV-3 strain in individuals aged 26–59 years was calculated from
the number of overt mild cases with primary DENV-3 infections
divided by the estimated total primary DENV-3 infections (Table
3). There were 1261 estimated primary DENV-3 infections in
individuals aged 26–59 years among which were 32 reported
cases, or one mild case for every 39.4 infections (2.45%, 95% CI 1.6–
3.4%). Employing a similar analysis, it was estimated that nearly all
secondary DENV-3 infections in the sequence DENV-1/3 were
overt (Table 3). This conclusion is based on the estimate that 631n individuals aged 26–59 years in the study cohort, with projections of total cases in
uba. Clinical cases reported from Playa District are described in Table 1
ections Tertiary infections Quaternary infections
DENV-2/3 DENV-1/2/3 DENV-2/4/3 DENV-1/2/4/3
8 24 1 6
840.8 2522.4 105.1 630.6
187/0 187/1 0/0
1:4.49 1:14.05 0
0 1:2627.5 0
z et al., 2008.21
Genderb
Black, n (%) Female, n (%) Male, n (%)
117 (45.17) 432 (41.78) 295 (40.75)
142 (54.83) 602 (58.22) 429 (59.25)
259 1034 724
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Almost the same number of mild and severe cases (n = 644) from
Playa District were attributed to infections in the sequence DENV-
1/3. Secondary DENV-2/3 infections were associated with mild
illnesses, the case:infection ratio was 1:4.49 (95% CI 1:5.77–
1:3.42), but no DHF/DSS cases were observed in the sequence
DENV-2/3. Tertiary dengue infections produced mild disease and
DHF infrequently, at 1:14 (95% CI 1:18–1:10) and 1:2627 (95% CI
1:3412–1:2115), respectively.
Table 4 displays dengue antibody prevalence observed in the
serological cohort by ethnic group (p = 0.52) and gender (p = 0.69).
No signiﬁcant differences were observed in any group.
4. Discussion
The technical underpinning of this study is based upon three
epidemiological attributes unique to Cuba. First, the introduction
and propagation of only one DENV at a time, such that the
sequence of the infecting serotypes is known. In other geographic
settings, where multiple serotypes are circulating at the same time
and continuously for several years/decades, it is difﬁcult to predict
the sequence of infection from a serosurvey due to the ‘original
antigenic sin’ phenomena that might occur. Second is the
comprehensive island-wide case reporting and surveillance
system that permitted near universal serological conﬁrmation of
cases. Third is the evidence that sera from individuals who had
unapparent DENV infections one or more years earlier, tested at a
1:30 dilution, circulate mono- or bivalent dengue neutralizing
antibodies that reliably match previous infection experi-
ence.7,12,13,20,24,33,36 The absence of DENV-1 and DENV-2 neutral-
izing antibodies in individuals aged 2–19 years conﬁrms the fact
that DENV-3 was the ﬁrst dengue introduction since 1977 and
1981. A retrospective seroepidemiological study of the DENV-3
epidemic of 2001–2002 was undertaken in 2003 using a 1%
random sample of the Playa District population, powered to
measure a DENV-3 antibody prevalence of 15%. Playa had the
highest number of reported dengue cases during the 2001–2002
epidemic.23,24 There is sufﬁcient congruence between the serolog-
ically studied sample and the general population of Playa (Table 1)
to warrant projection of serosurvey data to the entire population of
the municipality.
Among the population of Playa District, 7.2% suffered a DENV-3
infection, resulting in 13 104 infected individuals and 1806 clinical
cases. The number of overt dengue cases as determined by the
seroepidemiological study was quite similar to that reported to the
dengue surveillance system. However, as both systems may
potentially under-detect mild disease, it is possible that some
clinically overt cases were not notiﬁed.
Similar to other reports, this study found a much higher
incidence of asymptomatic than symptomatic dengue infections.37
As participants of the seroepidemiological survey were inter-
viewed almost 2 years after the epidemic, it is likely that some
individuals may not have remembered a case of mild disease.
However, this potential bias is diminished by the strength of the
active dengue surveillance system to recover virtually all dengue
cases.
From the 309 children aged 2–19 years, the data obtained
suggest that 2326 children experienced a primary DENV-3
infection in the district. Consistent with laboratory-based surveil-
lance studies of clinical cases reported from Havana during the past
20 years, no children had experienced any other DENV infection
during their lifetime. Attack rates of mild disease among children
and adolescents accompanying primary DENV-3 infections were
relatively high, there being one mild case for every 6.25 primary
DENV-3 infections (16%). Interestingly, primary DENV-3 infections
in adults aged 26–59 years were milder than in children, with onemild case for every 39.4 DENV-3 infections in adults (2.5%). During
the DENV-2 outbreak in Santiago de Cuba in 1997, very few mild
dengue cases occurred in children, but mild disease did occur in
26–59-year-olds at a ratio of 1 case to 33 infections (3.0%), similar
to the clinical expression of DENV-3 infections in this age group.13
This conﬁrms observations made previously in Thai children in
whom primary DENV-2 infections were mostly unapparent, while
primary DENV-3 infections were more severe.38
In previous seroepidemiological studies we observed that
secondary dengue infection rates are higher than primary infection
rates,12 due to the probability that over a long period of time
households either do or do not provide habitats for A. aegypti. Even
after periods of complete control, when vector mosquitoes are re-
introduced, households with permissive habitats again harbor A.
aegypti. When DENV is introduced, residents of these infested
households are at higher risk of infection than are the residents of
non-infested households. The likely positive correlation between
members of shared households will mean that the conﬁdence
intervals should in fact be wider than were obtained assuming
independence. However for the analysis it was assumed that all
individuals were independent, as some infections occur outside
the home, and also very few households showed more than one
member with anti-DENV-3 antibodies (data not shown).
In this study, the highest primary DENV-3 infection rate,
measured in susceptible children, was 5.5%. This can be compared
with the 11.8% DENV-3 infection rate in DENV immunes (Tables 2
and 3). An important observation made in 1997 was that when
secondary DENV-2 infections occurred 18–20 years after primary
DENV-1 infection, all such infections were clinically overt.13 This
was also true when DENV-3 infections occurred at an interval of
23–24 years after DENV-1 (Table 3). In Playa District, in addition to
the 625 mild cases we estimated to have experienced this infection
sequence, there were an additional 18 DHF/DSS cases, or a ratio of
mild:severe disease of 1:35 (95% CI 1:67–1:23). During the 1997
outbreak, secondary DENV-2 disease was somewhat more severe
than secondary DENV-3, the ratio of mild to severe cases being
22.8:1.13
Secondary infections in the sequence DENV-2/3 were not as
pathogenic as DENV-1/3 infections. There were 187 mild cases
detected without a single case of DHF/DSS. However, mild disease
accompanying secondary DENV-2/3 occurred quite frequently, at a
ratio of 1:4.49 (95% CI 1:5.77–1:3.42) secondary infections. Might
these differences be related to the ability of polyclonal human
DENV-2 antibodies to neutralize DENV-3? We plan to extend our
previous study of heterotypic DENV-1 and DENV-2 neutralizing
antibodies to DENV-3 viruses recovered from the 2001–2002
outbreak.17
In our study, tertiary infections were relatively common, there
being an estimated 2627 individuals infected in this sequence,
with mild disease estimated in 187 of these persons (7.1%), but
only a single case of DHF/DSS. This high ratio of tertiary infections
to overt severe dengue disease is consistent with a report
describing the rarity of hospitalized disease accompanying a
tertiary infection among Thai children.39 We also failed to ﬁnd
overt quaternary infections.
Previous studies suggested that white individuals had a higher
risk of developing DHF/DSS during DENV-1/2 infections than did
blacks, while both whites and blacks had similar infection
rates.7,12,13,40–42 Again in Playa, DENV-3 infection rates were
similar in whites and blacks (Table 4), while whites had higher
attack rates of DHF/DSS than did blacks.22
In conclusion, we have studied the implications of DENV-3
infections accompanying ﬁrst, second, or third sequential infec-
tions in individuals with DENV-1 and/or DENV-2 infections. Our
results add new evidence of the complexity of dengue pathogene-
sis, highlighting the role of infecting serotype and also the
M.G. Guzman et al. / International Journal of Infectious Diseases 16 (2012) e198–e203 e203sequence of the viral infection on the clinical outcome of a dengue
infection.
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